Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
www.theasianindependent.co.uk<br />
HEALTH<br />
<strong>January</strong> <strong>2019</strong><br />
15<br />
Diabetes drugs linked to heart disease risk: Study<br />
New York, Intake of<br />
two commonly used<br />
drugs to treat Type-2 diabetes<br />
carry a high risk of<br />
cardiovascular events<br />
such as heart attack,<br />
stroke, heart failure or<br />
amputation, warns a new<br />
study.<br />
<strong>The</strong> two drugs — sulfonylureas<br />
and basal<br />
insulin — are the second-line<br />
medication after<br />
metformin, a widely<br />
accepted initial Type-2<br />
diabetes treatment.<br />
<strong>The</strong> study, published<br />
in the journal JAMA<br />
Network Open, showed that<br />
patients who take one of these<br />
two drugs are 36 per cent more<br />
likely and twice as likely to<br />
experience cardiovascular<br />
harm.<br />
“People should know if the<br />
medications they are taking to<br />
treat their diabetes could lead to<br />
serious cardiovascular harm.<br />
This calls for a paradigm shift<br />
in the treatment of Type 2 diabetes,”<br />
said lead author<br />
Matthew O’Brien, Assistant<br />
Professor from the<br />
Northwestern University in the<br />
US. Physicians should consider<br />
prescribing newer classes of<br />
antidiabetic medications, such<br />
as GLP-1 agonists (liraglutide),<br />
SGLT-2<br />
inhibitors<br />
(empagliflozin)or DPP-4<br />
inhibitors (sitagliptin), more<br />
routinely after metformin,<br />
rather than sulfonylureas or<br />
basal insulin, suggest the<br />
researchers. <strong>The</strong>se drugs, however,<br />
are more expensive than<br />
the sulfonylureas, which is the<br />
main reason they are not as<br />
commonly prescribed.<br />
<strong>The</strong> study should force medical<br />
providers to think about<br />
cardiovascular effects of these<br />
drugs early in the course of diabetes<br />
treatment, and shift prescribing<br />
patterns to newer<br />
drugs that have more<br />
favourable cardiovascular profiles,the<br />
team noted.<br />
This was an observational<br />
study using data from 132,737<br />
patients with Type-2 diabetes<br />
who were starting second-line<br />
treatment.<br />
Novel drug to fight Alzheimer’s,<br />
PARKINSON’S DEVELOPED<br />
London, Scientists<br />
have developed a drug<br />
with potential to stop the<br />
breakdown of nerves and<br />
brain cells that may lead<br />
to Alzheimer’s,<br />
Parkinson’s and motor<br />
neuron disease.<br />
Alzheimer’s disease is<br />
the most common type of<br />
dementia, which includes<br />
memory loss, confusion<br />
and problems with speech<br />
and understanding.<br />
<strong>The</strong> drug is made up of<br />
“supercharged” vitamin<br />
A, which is found in vegetables<br />
like sprouts and carrots<br />
and miniature cabbages, the<br />
Daily Mail reported.<br />
<strong>The</strong> study showed that vitamin<br />
A turns into a chemical<br />
called retinoic acid when broken<br />
down by the body, which is<br />
crucial for the development of<br />
the nervous system.<br />
Higher levels of retinoic<br />
acid in the body could halt<br />
nerve damage and boost the<br />
number of nerve cells. “We are<br />
moving forward with a new<br />
therapeutic which could be<br />
used to help people with<br />
Alzheimer’s disease,” Peter<br />
McCaffery, lead author and<br />
Professor from the Aberdeen<br />
University in Scotland, was<br />
quoted as saying.<br />
“Our work is still at an early<br />
stage but we believe this is a<br />
positive development and the<br />
new drugs seem to protect<br />
nerve cells” he added.<br />
With vitamin A making a<br />
difference, it is important to<br />
find ways of tackling neurological<br />
conditions, McCaffery<br />
said.<br />
In addition, the drug may<br />
also benefit ALS or Lou<br />
Gehrig’s disease, which affects<br />
the muscles of the arms, legs,<br />
mouth and respiratory system.<br />
‘Super drug’ for pediatric blood<br />
cancer may soon be reality<br />
New York, A “super drug”<br />
that helps slow down the progression<br />
of blood cancer in<br />
children could soon become a<br />
reality, say researchers.<br />
Patients with leukemia have<br />
a very low percentage of red<br />
blood cells, making them anemic,<br />
and have approximately<br />
80 times more white blood<br />
cells than people without cancer.<br />
However, the survival rate<br />
is only 30 per cent for children<br />
diagnosed with MLLtranslocation<br />
leukemia, a cancer<br />
that affects the blood and<br />
bone marrow.<br />
“<strong>The</strong>se white blood cells<br />
infiltrate many of the tissues<br />
and organs of the affected individuals<br />
and is a major cause of<br />
death in leukemia patients,”<br />
said Ali Shilatifard, Professor<br />
at the Northwestern University<br />
in the US. “This is a monster<br />
cancer that we’ve been dealing<br />
with for many years in children.<br />
“We’re finally at a point<br />
where in five to 10 years, we<br />
can get a drug in kids that can<br />
be effective. If we can bring<br />
that survival rate up to 85 per<br />
cent, that’s a major accomplishment,”<br />
Shilatifard said. In<br />
the study, detailed in the journal<br />
Genes and Development,<br />
the team demonstrated that<br />
when a key protein responsible<br />
for leukemia, MLL, is stabilised,<br />
it slows the progression<br />
of the leukemia.<br />
This MLL stabilisation<br />
process could potentially work<br />
in cancers with solid tumours,<br />
such as breast or prostate cancer.<br />
<strong>The</strong> next step will be to<br />
combine the treatments from<br />
the past two years of<br />
research into a pediatric<br />
leukemia “super drug” to<br />
test on humans in a clinical<br />
trial, the researchers<br />
said. “This opens up a<br />
new therapeutic approach<br />
not only for leukemia,<br />
which is so important for<br />
the many children who<br />
are diagnosed with this terrible<br />
cancer, but also for other types<br />
of cancers that plague the population,”<br />
the study showed.<br />
<strong>The</strong> team also identified<br />
compounds that could slow<br />
cancer growth by interrupting<br />
a gene transcription process<br />
known as “Super Elongation<br />
Complex” (SEC).<br />
Mindfulness strategies may<br />
help shed excess weight<br />
LONDON : Mindfulness training could be<br />
the key to support weight loss in individuals with<br />
obesity, thereby facilitating healthier eating<br />
behaviours, as per a new study.<br />
Mindfulness is a mind-body<br />
practice where individuals learn<br />
to achieve heightened awareness<br />
of their current state of<br />
mind and immediate environment<br />
in the present moment.<br />
<strong>The</strong> study showed that individuals<br />
who participated in<br />
mindfulness training as part of<br />
an intensive weight management<br />
programme lost three kilograms<br />
of weight in six months<br />
than others who participated in<br />
obesity management programme.<br />
"This research is significant<br />
as we have shown that<br />
problematic eating behaviour<br />
can be improved with mindfulness application,"<br />
said Petra Hansona, lead researcher and postdoctoral<br />
student from the University of<br />
Warwickshire in the UK. "Mindfulness has huge<br />
potential as a strategy for achieving and maintaining<br />
good health and wellbeing," said Thomas<br />
M. Barber, Associate Professor at the varsity.<br />
Focus should be on enabling the populace to<br />
make appropriate lifestyle decisions and empowering<br />
subsequent salutary behaviour change, said<br />
Barber.<br />
For the study, the team examined<br />
weight loss among a small<br />
group of people who were attending<br />
the multidisciplinary tier 3<br />
weight management programme.<br />
Findings, published in the<br />
Journal of Clinical Endocrinology<br />
and Metabolism, showed that individuals<br />
who attended only one or<br />
two courses lost, on average, 0.9<br />
kilograms (2 pounds) during the<br />
same period. Conversely, those<br />
who did not complete the course<br />
tended to weigh more than those<br />
who finished the group mindfulness<br />
course. "Individuals who<br />
completed the course said they<br />
were better able to plan meals in advance and felt<br />
more confident in self-management of weight<br />
loss moving forward," said Hanson. Obesity<br />
worldwide has nearly tripled since 1975, according<br />
to the World Health Organisation. As of<br />
2016, more than 1.9 billion adults worldwide<br />
met the criteria for overweight or obesity.<br />
Women with slim hips may develop diabetes, heart attacks<br />
London : While putting on weight is dangerous<br />
for health, women who have slim hips could<br />
be at risk of diabetes and heart attacks, finds a<br />
new research.<br />
<strong>The</strong> study showed that putting on weight<br />
around the hips is actually safer than accumulation<br />
around the belly or around other major<br />
organs such as the liver or pancreas.<br />
<strong>The</strong> reason could be because some women are<br />
genetically less able to store fat at the hips,<br />
which puts them at risk of Type-2 diabetes and<br />
heart disease.<br />
Also, putting on fat is more likely to circulate<br />
in the blood.<br />
“This means that individuals with this genetic<br />
make-up preferentially store their excess fat in<br />
the liver, muscles or pancreas, or in their blood in<br />
the form of circulating fats and sugar, any of<br />
which can lead to a higher disease risk,” said<br />
Luca Lotta, lead researcher from the University<br />
of Cambridge.<br />
“It may seem counter-intuitive to think that<br />
some people with less fat around their hips are at<br />
higher risk of diabetes or heart disease,” said<br />
Lotta. For the study, the researchers studied the<br />
genetic profiles of more than 600,000 women.<br />
<strong>The</strong>y identified two specific groups of genetic<br />
variants — one that lowers fat around the hips<br />
and another increasing fat around the waist and<br />
belly.<br />
Findings, published in the JAMA medical<br />
journal, showed that both of the genetic variants<br />
identified were associated with higher risk of<br />
Type-2 diabetes and heart attacks.<br />
Genetics which specifically change fat distribution<br />
by lowering fat storage around the hips<br />
increase risk of disease independent of, and in<br />
addition to, mechanisms that affect abdominal<br />
fat storage, the study noted.